Drugs for Neglected Diseases initiative (DNDi) and the World Health Organisation (WHO) held a joint symposium on “Progress Made and Challenges Ahead in Clinical Research and Development of New Treatments for Human African Trypanosomiasis” followed by a Public Event organized by DNDi, the HAT Platform, along with NECT partners to celebrate the availability of the NECT treatment (improved treatment for sleeping sickness).
DNDi-WHO Symposium Program:
“Progress Made and Challenges Ahead in Clinical Research and Development
of New Treatments for Human African Trypanosomiasis”
Nifurtimox-Eflornithine Combination Therapy
Tuesday, 22 September, as of 6 pm, in Victoria Ballroom
Chairs: Pere Simarro (WHO/NTD) + Fred Kansiime (COCTU/Uganda)
Presentations
“National control program experience in conducting and incorporating clinical research into its activities”
by Gedeão Vatunga (ICCT, Angola)
“MSF recent experiences in DRC and CAR”
by Laurence Flevaud (MSF Spain)
“Recent progress in discovering new drugs: fexinidazole and other candidates in the pipeline”
by Olaf Valverde (DNDi, Switzerland)
“NECT: an improved treatment for stage 2 HAT. Clinical trial results and ongoing research”
by Wilfried Mutombo (PNLTHA, DRC)
Followed by a PUBLIC EVENT and a COCKTAIL as of 7.20 pm, organized by DNDi, the HAT Platform, along with NECT partners and in presence of the Health Minister of Uganda.
